Fredun Pharmaceuticals Limited Share Price

Equities

FREDUN6

INE194R01017

Pharmaceuticals

Delayed Bombay S.E. 05:55:29 03/05/2024 BST 5-day change 1st Jan Change
914 INR -1.17% Intraday chart for Fredun Pharmaceuticals Limited +10.44% +5.21%

Financials

Sales 2022 2.24B 26.93M 2.15B Sales 2023 2.75B 32.95M 2.62B Capitalization 3.57B 42.85M 3.41B
Net income 2022 63M 756K 60.2M Net income 2023 108M 1.3M 103M EV / Sales 2022 2.07 x
Net Debt 2022 586M 7.02M 560M Net Debt 2023 831M 9.97M 794M EV / Sales 2023 1.6 x
P/E ratio 2022
64.1 x
P/E ratio 2023
32.2 x
Employees 260
Yield 2022
0.08%
Yield 2023
0.09%
Free-Float 41.59%
More Fundamentals * Assessed data
Dynamic Chart
Fredun Pharmaceuticals Secures Orders from Sea Countries, Expands Product Development in Veterinary Care, and Advances Orthopaedic Applications CI
Fredun Pharmaceuticals Limited Announces Appointment of Ms. Daisy Cyril Dsouza as Additional Independent Director CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Fredun Pharmaceuticals Limited Declared A Dividend At 7% on the Equity Shares of the Company for the Financial Year Ended March 31, 2023 CI
Fredun Pharmaceuticals Limited Proposes Dividend for the Financial Year Ended March 31, 2023 CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Fredun Pharmaceuticals Limited Approves the Resignation of Dr. Chandrakant Shah as Independent Director CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Fredun Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2022-23 CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Fredun Pharmaceuticals Limited announced that it has received INR 275.691377 million in funding CI
Fredun Pharmaceuticals Limited Announces Change in Registered Office Address CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Fredun Pharmaceuticals Limited Approves Dividend for the Financial Year Ended March 31, 2022 CI
Fredun Pharmaceuticals Limited announced that it expects to receive INR 284.662157 million in funding CI
More news
1 day-1.17%
1 week+10.44%
Current month+27.42%
1 month+19.89%
3 months+10.02%
6 months+7.68%
Current year+5.21%
More quotes
1 week
752.00
Extreme 752
988.80
1 month
717.05
Extreme 717.05
988.80
Current year
650.00
Extreme 650
1 054.00
1 year
650.00
Extreme 650
1 249.00
3 years
351.20
Extreme 351.2
1 428.00
5 years
103.00
Extreme 103
1 428.00
10 years
12.50
Extreme 12.5
1 428.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 37 14/09/06
Chief Executive Officer 79 07/06/87
Compliance Officer - 27/01/22
Members of the board TitleAgeSince
Chief Executive Officer 79 07/06/87
Director/Board Member 54 29/05/15
Director/Board Member 75 29/09/15
More insiders
Date Price Change Volume
03/05/24 914 -1.17% 1 123
02/05/24 924.8 -1.15% 5,267
30/04/24 935.6 +0.13% 12,216
29/04/24 934.4 +10.49% 55,365
26/04/24 845.8 +0.16% 6,170

Delayed Quote Bombay S.E., May 03, 2024 at 05:55 am

More quotes
Fredun Pharmaceuticals Ltd. is an India-based pharmaceutical company. The Company is primarily engaged in the business of pharmaceuticals and healthcare. The Company operates through four segments: Generics (Exports & Fredun Gx), Pet Healthcare (Freossi), Nutraceuticals (Fredun Nutrition) and Cosmeceuticals (Bird and Beauty or BnB). It offers a range of products, including antihypertensive, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary /herbal supplements, nutraceuticals, and other healthcare products along with animal healthcare products. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.
More about the company
  1. Stock Market
  2. Equities
  3. FREDUN6 Stock